Sign up to save your podcasts
Or
Share ACC CardiaCast: Which Patients Can Benefit from the Newly-Approved Cardiac Myosin Inhibitor Recently Approved for HCM
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ACC CardiaCast: Which Patients Can Benefit from the Newly-Approved Cardiac Myosin Inhibitor Recently Approved for HCM
In this episode, Drs. Matt Martinez and Sara Saberi discuss the recent approval by the FDA of the cardiac myosin inhibitor Mavacamten for the treatment of hypertrophic cardiomyopathy, and what sorts of patients are best suited for this treatment.
View all episodes
By American College of Cardiology
4.4
3737 ratings
In this episode, Drs. Matt Martinez and Sara Saberi discuss the recent approval by the FDA of the cardiac myosin inhibitor Mavacamten for the treatment of hypertrophic cardiomyopathy, and what sorts of patients are best suited for this treatment.
More shows like ACC CardiaCast
View all
JAMA Editors' Summary
136 Listeners
NEJM This Week
319 Listeners
JAMA Clinical Reviews
496 Listeners
JACC This Week
170 Listeners
This Week in Cardiology
884 Listeners
Mayo Clinic Talks
291 Listeners
The Curbsiders Internal Medicine Podcast
3,344 Listeners
Eagle's Eye View: Your Weekly CV Update From ACC.org
140 Listeners
Core IM | Internal Medicine Podcast
1,159 Listeners
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
61 Listeners
Annals On Call Podcast
195 Listeners
JAMA Medical News
90 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
364 Listeners
Run the List
252 Listeners
Cardionerds: A Cardiology Podcast
430 Listeners